Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07064759 · ClinicalTrials.gov registry record · Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by 4D Molecular Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
480
Enrollment target
20
Study locations

NCT07064759: Recruiting Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by 4D Molecular Therapeutics.

NCT07064759 is a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) that is actively recruiting participants, run by 4D Molecular Therapeutics. The registered enrollment target is 480 participants, above the 155-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (210% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07064759, a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), is actively recruiting participants, sponsored by 4D Molecular Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
480 participants
Enrollment target
20
Study locations

Study Summary

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Conditions Studied

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • BIOLOGICAL 4D-150 IVT (3E10 vg/eye)
  • BIOLOGICAL EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Study Locations (20)

California

  • Retinal Diagnostic Center - Campbell
  • Retina Consultants of Orange County - Fullerton
  • West Coast Retina Medical Group - San Francisco

Maryland

  • The Retina Care Center - Baltimore
  • Cumberland Valley Retina Consultants - Hagerstown
  • Mid Atlantic Retina Specialist - Hagerstown

Arizona

  • Barnet Dulaney Perkins Eye Center - Sun City
  • Retina Associates - Tucson

Florida

  • ClearVista Clinical Research - Hudson
  • Retina Vitreous Associates of Florida - Tampa

New York

  • New York Presbyterian Hospital - Columbia University Medical Center - New York
  • Vitreoretinal Consultants of NY - Westbury

South Carolina

  • Charleston Neuroscience Institute, LLC - Bluffton
  • Carolina Eyecare - Mt. Pleasant

Colorado

  • Southwest Retina Consultants - Durango

Georgia

  • Thomas Eye Group - Sandy Springs

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2025-07-22
Est. Completion 2029-02
Phase Phase 3
4D Molecular Therapeutics

9 total trials

What NCT07064759 shows while recruiting

NCT07064759 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 155-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (210% higher).

The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 2 interventions - of which 4D-150 IVT (3E10 vg/eye) is the first listed.

NCT07064759 names 20 study sites across 12 states, led by California, Maryland, Arizona.

Frequently Asked Questions

What is clinical trial NCT07064759 about?

NCT07064759 is a clinical study titled "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration". A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

What is the current status of trial NCT07064759?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-07-22. Estimated completion is 2029-02.

What conditions does trial NCT07064759 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).

What interventions are being tested in trial NCT07064759?

The interventions under investigation include: 4D-150 IVT (3E10 vg/eye) (BIOLOGICAL), EYLEA® (aflibercept) Injection 2 mg (0.05mL) (BIOLOGICAL).

Who is sponsoring clinical trial NCT07064759?

This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07064759 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration (nAMD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07064759's enrollment target sits among peer trials

480 1st of 9 higher than 9 of 9 other Neovascular Age-related Macular Degeneration (nAMD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration (nAMD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01954992 · 480 participants · Phase 3

    Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

  • NCT03023696 · 480 participants · NA

    Can Prophylactic Foraminotomy Prevent C5 Palsy

  • NCT04948060 · 480 participants · NA

    Tribally Engaged Approaches to Lung Screening (TEALS)

  • NCT05053230 · 480 participants · NA

    A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07064759

Source: ClinicalTrials.gov NCT07064759, the US trial registry maintained by the National Library of Medicine. NCT07064759 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.